NCT02647112View on ClinicalTrials.gov

Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma

NACompletedINTERVENTIONAL
Enrollment

1,050

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Bladder Cancer
Interventions
OTHER

Bladder EpiCheck

Urine test for the monitoring of bladder cancer recurrence

Trial Locations (6)

Unknown

Tubingen University Medical Center, Tübingen

Meir Medical Center, Kfar Saba

AMC Medical Center, Amsterdam

ZGT Medical Center, Hengelo

Radboud University Medical Center, Nijmegen

Vall D'Hebron Medical Center, Barcelona

Sponsors

Lead Sponsor

Nucleix Ltd.
All Listed Sponsors
lead

Nucleix Ltd.

INDUSTRY

NCT02647112 - Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma | Biotech Hunter | Biotech Hunter